Your browser doesn't support javascript.
loading
Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions.
Méreaux, Jean-Loup; Davoine, Claire-Sophie; Pellerin, David; Coarelli, Giulia; Coutelier, Marie; Ewenczyk, Claire; Monin, Marie-Lorraine; Anheim, Mathieu; Le Ber, Isabelle; Thobois, Stéphane; Gobert, Florent; Guillot-Noël, Léna; Forlani, Sylvie; Jornea, Ludmila; Heinzmann, Anna; Sangare, Aude; Gaymard, Bertrand; Guyant-Maréchal, Lucie; Charles, Perrine; Marelli, Cecilia; Honnorat, Jérôme; Degos, Bertrand; Tison, François; Sangla, Sophie; Simonetta-Moreau, Marion; Salachas, François; Tchikviladzé, Maya; Castelnovo, Giovanni; Mochel, Fanny; Klebe, Stephan; Castrioto, Anna; Fenu, Silvia; Méneret, Aurélie; Bourdain, Frédéric; Wandzel, Marion; Roth, Virginie; Bonnet, Céline; Riant, Florence; Stevanin, Giovanni; Noël, Sandrine; Fauret-Amsellem, Anne-Laure; Bahlo, Melanie; Lockhart, Paul J; Brais, Bernard; Renaud, Mathilde; Brice, Alexis; Durr, Alexandra.
Afiliação
  • Méreaux JL; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Davoine CS; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Pellerin D; Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery, University College London, London,
  • Coarelli G; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Unité de Génétique Clinique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Coutelier M; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Ewenczyk C; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Unité de Génétique Clinique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Monin ML; Centre de Reference Maladies Rares « Neurogénétique ¼, Service de Génétique Médicale, Bordeaux University Hospital (CHU Bordeaux), 33000, Bordeaux, France.
  • Anheim M; Department of Neurology, Strasbourg University Hospital, 67098, Strasbourg, France; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964, CNRS-UMR7104, University of Strasbourg, 67400, Illkirch-Graffenstaden, France.
  • Le Ber I; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Thobois S; Department of Neurology C, Expert Parkinson Centre NS-Park/F-CRIN, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, 69677, Bron, France; Marc Jeannerod Cognitive Neuroscience Institute, CNRS, UMR 5229, Bron, France; Faculté de Médecine Et de Maïeutique Lyon Sud Charles Mérieux, Univ
  • Gobert F; Neuro-Intensive Care Unit, Hospices Civils de Lyon, Neurological Hospital Pierre-Wertheimer, Lyon, France; University Lyon I, Villeurbanne, France.
  • Guillot-Noël L; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Forlani S; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Jornea L; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Heinzmann A; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Sangare A; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Department of Neurophysiology, University Hospital Group APHP-Sorbonne University, Pitié-Salpêtrière Site, Paris, France.
  • Gaymard B; Department of Neurophysiology, University Hospital Group APHP-Sorbonne University, Pitié-Salpêtrière Site, Paris, France.
  • Guyant-Maréchal L; Neurophysiology Department, Rouen University Hospital, Rouen, France; Medical Genetics Department, Rouen University Hospital, Rouen, France.
  • Charles P; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Unité de Génétique Clinique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Marelli C; MMDN, University Montpellier, EPHE, INSERM and Expert Center for Neurogenetic Diseases, CHU, 34095, Montpellier, France.
  • Honnorat J; Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, MeLiS Institute UMR CNRS 5284 - INSERM U1314, Université Claude Bernard Lyon 1, Lyon, France.
  • Degos B; Neurology Department, Avicenne Hospital, APHP, Hôpitaux Universitaires de Paris-Seine Saint Denis (HUPSSD), Sorbonne Paris Nord, Réseau NS-PARK/FCRIN, Bobigny, France.
  • Tison F; Institut des Maladies Neurodégénératives-Clinique (IMNc), University Hospital Bordeaux, Bordeaux, France; Institut des Maladies Neurodégénératives, CNRS, UMR 5293, Bordeaux University, Bordeaux, France.
  • Sangla S; Neurology Department, Hôpital Fondation Adolphe de Rothschild, Paris, France.
  • Simonetta-Moreau M; Department of Neurology, University Hospital of Toulouse, 31300, Toulouse, France; Toulouse NeuroImaging Center (ToNIC), Inserm, UPS, Université de Toulouse, 31024, Toulouse, France; Clinical Investigation Center (CIC 1436), Toulouse University Hospital, INSERM, 31059, Toulouse, France.
  • Salachas F; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Département de Neurologie, Assistance Publique Hôpitaux de Paris (APHP), Centre de Référence SLA Ile de France, Hôpital de la Pitié-Salpêtrière, Paris, France.
  • Tchikviladzé M; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Castelnovo G; Department of Neurology, Nîmes University Hospital, Hopital Caremeau, Nîmes, France.
  • Mochel F; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Klebe S; Department of Neurology, University Hospital Essen, Essen, Germany.
  • Castrioto A; Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France.
  • Fenu S; Unit of Rare Neurological Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Méneret A; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Département de Neurologie, Hôpital de la Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.
  • Bourdain F; Service de Neurologie, Centre Hospitalier de la Côte Basque, Bayonne, France.
  • Wandzel M; Laboratoire de Génétique Médicale, CHRU Nancy, Université de Lorraine, INSERM UMR_S1256, NGERE, Nancy, France.
  • Roth V; Laboratoire de Génétique Médicale, CHRU Nancy, Université de Lorraine, INSERM UMR_S1256, NGERE, Nancy, France.
  • Bonnet C; Laboratoire de Génétique Médicale, CHRU Nancy, Université de Lorraine, INSERM UMR_S1256, NGERE, Nancy, France.
  • Riant F; Service de Génétique Moléculaire Neurovasculaire, AP-HP, Saint Louis Hospital, Paris, France.
  • Stevanin G; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Bordeaux University (Université de Bordeaux), Equipe « Neurogénétique Translationnelle - NRGEN ¼, INCIA CNRS UMR5287, EPHE, 33000, Bordeaux, France.
  • Noël S; Unité de Neurogénétique Moléculaire et Cellulaire, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Fauret-Amsellem AL; Unité de Neurogénétique Moléculaire et Cellulaire, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Bahlo M; Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia.
  • Lockhart PJ; Bruce Lefroy Centre, Murdoch Children's Research Institute and Department of Paediatrics, University of Melbourne, Parkville, VIC, 3052, Australia.
  • Brais B; Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada.
  • Renaud M; Service de Génétique Clinique et de Neurologie, Hôpital Brabois, Nancy, France; INSERM Unité 1256 N-GERE (Nutrition-Genetics and Environmental Risk Exposure), Université de Lorraine, Nancy, France.
  • Brice A; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France.
  • Durr A; Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Paris, France; Unité de Génétique Clinique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France. Electronic address: alexandra.durr@icm-institute.org.
EBioMedicine ; 99: 104931, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38150853
ABSTRACT

BACKGROUND:

SCA27B caused by FGF14 intronic heterozygous GAA expansions with at least 250 repeats accounts for 10-60% of cases with unresolved cerebellar ataxia. We aimed to assess the size and frequency of FGF14 expanded alleles in individuals with cerebellar ataxia as compared with controls and to characterize genetic and clinical variability.

METHODS:

We sized this repeat in 1876 individuals from France sampled for research purposes in this cross-sectional study 845 index cases with cerebellar ataxia and 324 affected relatives, 475 controls, as well as 119 cases with spastic paraplegia, and 113 with familial essential tremor.

FINDINGS:

A higher frequency of expanded allele carriers in index cases with ataxia was significant only above 300 GAA repeats (10.1%, n = 85) compared with controls (1.1%, n = 5) (p < 0.0001) whereas GAA250-299 alleles were detected in 1.7% of both groups. Eight of 14 index cases with GAA250-299 repeats had other causal pathogenic variants (4/14) and/or discordance of co-segregation (5/14), arguing against GAA causality. We compared the clinical signs in 127 GAA≥300 carriers to cases with non-expanded GAA ataxia resulting in defining a key phenotype triad onset after 45 years, downbeat nystagmus, episodic ataxic features including diplopia; and a frequent absence of dysarthria. All maternally transmitted alleles above 100 GAA were unstable with a median expansion of +18 repeats per generation (r2 = 0.44; p < 0.0001). In comparison, paternally transmitted alleles above 100 GAA mostly decreased in size (-15 GAA (r2 = 0.63; p < 0.0001)), resulting in the transmission bias observed in SCA27B pedigrees.

INTERPRETATION:

SCA27B diagnosis must consider both the phenotype and GAA expansion size. In carriers of GAA250-299 repeats, the absence of documented familial transmission and a presentation deviating from the key SCA27B phenotype, should prompt the search for an alternative cause. Affected fathers have a reduced risk of having affected children, which has potential implications for genetic counseling.

FUNDING:

This work was supported by the Fondation pour la Recherche Médicale, grant number 13338 to JLM, the Association Connaître les Syndrome Cérébelleux - France (to GS) and by the European Union's Horizon 2020 research and innovation program under grant agreement No 779257 ("SOLVE-RD" to GS). DP holds a Fellowship award from the Canadian Institutes of Health Research (CIHR). SK received a grant (01GM1905C) from the Federal Ministry of Education and Research, Germany, through the TreatHSP network. This work was supported by the Australian Government National Health and Medical Research Council grants (GNT2001513 and MRFF2007677) to MB and PJL.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia de Friedreich / Ataxia Cerebelar Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia de Friedreich / Ataxia Cerebelar Idioma: En Ano de publicação: 2024 Tipo de documento: Article